Observational Study of Recombinant Factor-VIII-Fc, Eloctate, in Hemophilia Patients with and without Inhibitors

被引：0
|
作者：
Ebbert, Patrick T.
Ragni, Margaret V.
Xavier, Frederico
Malec, Lynn M.
Seaman, Craig D.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3689
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Recombinant coagulation factor VIII Fc-von Willebrand factor fusion protein Treatment of hemophilia A
    Villarreal-Martinez, Laura
    Zamora-Martinez, Paola Lizeth
    DRUGS OF THE FUTURE, 2022, 47 (10) : 711 - 714
  • [32] Inactivation of animal factor VIII by human factor VIII inhibitors: Investigation of plasma from patients with inhibitors in congenital Hemophilia A and from patients with acquired Hemophilia A
    Aumann, V
    Lutze, G
    Lutze, G
    Franke, D
    Mittler, U
    32ND HEMOPHILIA SYMPOSIUM, 2003, : 275 - 279
  • [33] Inhibitors of Factor VIII in Hemophilia REPLY
    Viel, Kevin R.
    Kasper, Carol K.
    Howard, Tom E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (03): : 310 - 310
  • [34] ADHERENCE TO PROPHYLAXIS WITH RECOMBINANT FACTOR VIII FC IN HAEMOPHILIA A PATIENTS
    Pitance, V.
    Lienhart, A.
    Meunier, S.
    Le Quellec, S.
    Rugeri, L.
    Desage, S.
    Chamouard, V.
    HAEMOPHILIA, 2020, 26 : 129 - 129
  • [35] IMPACT OF SWITCHING PROPHYLAXIS TREATMENT FROM FACTOR VIII TO EMICIZUMAB IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
    Escobar, Miguel
    Agrawal, Neha
    Chatterjee, Sagnik
    Bhattacharya, Swastik
    Caicedo, Jorge
    Bullano, Michael
    Schultz, Robert G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E34 - E34
  • [36] Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors
    Escobar, Miguel
    Agrawal, Neha
    Chatterjee, Sagnik
    Bhattacharya, Swastik
    Caicedo, Jorge
    Bullano, Michael
    Schultz, Bob G. G.
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 574 - 580
  • [37] FACTOR-VIII INHIBITORS IN HEMOPHILIA
    不详
    LANCET, 1983, 1 (8327): : 742 - 743
  • [38] Emicizumab for hemophilia A with factor VIII inhibitors
    Young, Guy
    Callaghan, Michael
    Dunn, Amy
    Kruse-Jarres, Rebecca
    Pipe, Steven
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (11) : 835 - 846
  • [39] A multicenter study of recombinant factor VIII (Recombinate(TM)) in previously treated patients with hemophilia A
    White, GC
    Courter, S
    Bray, GL
    Lee, M
    Gomperts, ED
    White, G
    Cooper, H
    Haire, W
    Brettler, D
    Kisker, T
    Hoots, K
    Shapiro, A
    Halie, MR
    Mannucci, PM
    Scharrer, I
    Brackmann, HH
    Gordon, EM
    Goldsmith, J
    Hilgartner, M
    Gill, J
    Laurian, Y
    Larrieu, Y
    Kessler, C
    Pai, MKR
    Lusher, JM
    Neufeld, E
    Ewenstein, B
    Schulman, S
    Morfini, M
    Addiego, JE
    Vermylen, JG
    Krill, CE
    Ingerslev, J
    THROMBOSIS AND HAEMOSTASIS, 1997, 77 (04) : 660 - 667
  • [40] Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype
    Driessler, Frank
    Miguelino, Maricel G.
    Pierce, Glenn F.
    Peters, Robert T.
    Sommer, Jurg M.
    BLOOD COAGULATION & FIBRINOLYSIS, 2017, 28 (07) : 540 - 550
12345